The Saudi pharmaceutical market grew 9.1% in 2024 and is forecast to compound at 7.6% through 2032. Drug spending is rising faster than total healthcare expenditure, faster than insurance premium growth, and faster than the overall medical inflation curve. The Council of Health Insurance recognised this trajectory in September 2022 with circular N°289, which established generic substitution as policy. The first analysis of that policy on NPHIES claims data confirms it is working: generic utilisation rose from 70% to 76% over the first 10 months, generating SAR 335 million in actual savings, with another SAR 228 million identified as available but unrealised. The policy direction is set. The governance gap is operational.
Most Saudi insurers do not have a pharmacy benefit management function in any meaningful sense. They have claims adjudication. They have formularies they have adopted from the CHI essential benefit package. They have pharmacy networks. What they do not have is the analytical, contractual, and governance architecture that distinguishes a PBM capability from a claims-processing operation: the systematic management of drug spending as a strategic discipline rather than a reactive expense category.
That gap is becoming material. The drug spend trajectory, the generic substitution incentive structure, the AR-DRG transition, and the NPHIES drug coding infrastructure are all now in place. The organisations that build PBM governance capability around them will manage their pharmacy loss ratio through the next reform cycle. The organisations that continue to treat pharmacy as a claims category will not.
What PBM Governance Actually Is
Pharmacy benefit management as a discipline emerged in the United States in the 1980s as a response to a specific structural problem: that drug spending was growing faster than total healthcare cost, that drug pricing was opaque, and that insurers needed analytical capability to manage prescribing patterns at the population level rather than the individual claim level. PBMs developed three core competencies: formulary management, network contracting, and prescribing intelligence. None of them is a claims processing function. All of them require analytical infrastructure that most Saudi insurers have not built.
Formulary management means deciding which drugs are covered, at which tier, with which prior authorisation requirements, based on a defined methodology that considers clinical evidence, cost-effectiveness, and budget impact. The CHI publishes the essential benefit package and the Insurance Drug Formulary, but those documents are floors, not ceilings. A mature PBM uses them as a starting point and builds an organisation-specific formulary that reflects the actual risk profile of the insured population.
Network contracting means negotiating reimbursement rates with pharmacy chains, retail pharmacies, hospital pharmacies, and specialty pharmacies based on dispensed volume, generic dispensing rate, and adherence support capability. Most Saudi insurers contract pharmacies on standard reimbursement schedules without performance differentiation. Mature PBMs differentiate aggressively.
Prescribing intelligence means analysing prescribing patterns at the prescriber level, the drug class level, and the patient level: identifying outlier prescribers, detecting therapeutic substitution opportunities, and intervening on prescribing patterns that drive disproportionate cost without proportional clinical benefit. The Saudi market has the data. NPHIES contains every prescription transaction with SFDA codes attached. The intelligence does not exist because the analytical layer to interrogate that data has not been built.
The CHI generic substitution policy did the strategic work. It established the principle, set the incentive direction, and produced quantifiable savings within the first year. The remaining SAR 228 million in unrealised savings is not a policy gap. It is a PBM governance gap at the insurer level.
Where Saudi Insurers Are Today
The Saudi insurance market entered the post-CHI-289 environment with limited PBM infrastructure. The dominant operational pattern is claims adjudication: pharmacy submits a claim through NPHIES, the claim is checked against eligibility and the formulary, payment is made or denied. The processing is fast, automated, and tightly integrated. It is also analytically passive. The insurer learns nothing from the claim that informs future cost management beyond the individual payment decision.
That passivity is the issue. The Saudi pharmaceutical market is dominated by branded drugs at 51 to 54% market share, with generics holding 36% and biosimilars at 10%. The CHI policy is pushing generic utilisation upward, but the rate of substitution is insurer-dependent: it depends on how aggressively the insurer manages its formulary, contracts its network, and intervenes on prescribing. Insurers without active PBM governance are leaving substitution to default behaviour at the pharmacy counter. The data shows that default behaviour is not capturing the full available savings: SAR 228 million remains on the table.
Three structural factors will make the gap larger if it is not closed. The pharmaceutical market is growing at 7.6% CAGR through 2032, faster than insurance premium growth. Specialty drugs in oncology (29% of the market), cardiology (21%), and diabetes (17%) are driving disproportionate cost concentration in high-acuity therapeutic areas. And the NISS expansion to 23 million beneficiaries is adding population without adding immediate analytical capacity.
The PBM Capabilities the Saudi Market Now Requires
The capabilities most insurers lack
- Tiered formulary structure with documented selection criteria beyond CHI essential benefits
- Prior authorisation protocols for high-cost drugs with defined clinical pathways
- Therapeutic substitution policies with documented evidence base
- Annual formulary review cycle with budget impact assessment
- Specialty drug management programme for oncology, biologics, and rare disease
The analytical capabilities most insurers lack
- Prescriber-level prescribing pattern monitoring and outlier identification
- Therapeutic class spending analysis with cost-per-member-per-month tracking
- Adherence and persistence measurement for chronic disease therapies
- Polypharmacy risk identification at the patient level
- Drug-drug interaction and inappropriate prescribing pattern detection
The Provider Side of the Equation
PBM governance is not only a payer concern. Hospitals and clinics with significant pharmacy operations have the same analytical question, viewed from the opposite side of the transaction. Hospital pharmacies hold 41.8% of pharmaceutical distribution market share and are particularly exposed to the AR-DRG transition: when reimbursement moves from itemised to bundled, the cost of inpatient drugs is no longer a pass-through expense but a margin pressure on the episode payment.
Providers operating in this environment need their own pharmacy cost governance: formulary discipline within the hospital, generic substitution protocols at the dispensing point, and pharmacy spending analytics that distinguish between drug categories whose cost is variable by clinical decision and those whose cost is fixed by therapeutic necessity. The hospital pharmacy that operates as a cost centre passing through expense to the insurer will face material margin compression once AR-DRG bundling is in full effect. The hospital pharmacy that operates as a managed cost discipline will not.
The NPHIES Drug Data Asset
The infrastructure to support PBM analytics already exists. NPHIES validates every drug claim against SFDA codes and the CHI Insurance Drug Formulary. The platform holds prescribing data by provider, dispensing data by pharmacy, and longitudinal medication history at the patient level. The Value in Health Regional Issues study published in May 2025 demonstrated what is possible with this data: a 10-month retrospective analysis of post-CHI-289 substitution patterns that accurately quantified savings and identified the specific therapeutic areas where additional substitution potential remains, including Antineoplastic and Immunomodulating agents.
That study was conducted at the system level by researchers with academic data access. The same analytical methodology is available to any insurer with the analytical capability to apply it to its own claims book. The data is the same. The platform is the same. The decision to use it is what separates organisations that will manage their pharmacy spending through the reform cycle from those that will react to it.
Pharmacy is now the second-largest line of insurance medical expense after inpatient care. Treating it as a claims processing category rather than a managed governance discipline is no longer a viable operating model in the Saudi market. The PBM capability gap is the most underestimated cost containment lever in the system today.